What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
Richard A FurieEric F MorandIan N BruceDavid Alan IsenbergRonald van VollenhovenGabriel AbreuLilia PinedaRaj TummalaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
BICLA response is associated with clinical benefit in SLE assessments, PROs, and medical resource utilization, confirming its value as a clinical trial end point that is associated with measures important to patient care.